Delta-Fly Pharma, Inc. (TYO:4598)

Japan flag Japan · Delayed Price · Currency is JPY
185.00
-5.00 (-2.63%)
Apr 3, 2026, 3:30 PM JST
Market Cap2.25B -59.0%
Revenue (ttm)n/a
Net Income-1.66B
EPS-152.73
Shares Out12.16M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume337,600
Average Volume442,760
Open192.00
Previous Close190.00
Day's Range184.00 - 194.00
52-Week Range184.00 - 793.00
Beta-1.06
RSI32.24
Earnings DateMay 15, 2026

About Delta-Fly Pharma

Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 13
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4598
Full Company Profile

Financial Performance

Financial Statements